Document is current
Any future updates will be listed below
-
Authors
Schubert, Maria-Luisa
Schmitt, Anita
Hückelhoven-Krauss, Angela
Neuber, Brigitte
Kunz, Alexander
Waldhoff, Philip
Vonficht, Dominik
Yousefian, Schayan
Jopp-Saile, Lea
Wang, Lei
Korell, Felix
Keib, Anna
Michels, Birgit
Haas, Dominik
Sauer, Tim
Derigs, Patrick
Kulozik, Andreas
Kunz, Joachim
Pavel, Petra
Laier, Sascha
Wuchter, Patrick
Schmier, Johann
Bug, Gesine
Lang, Fabian
Gökbuget, Nicola
Casper, Jochen
Görner, Martin
Finke, Jürgen
Neubauer, Andreas
Ringhoffer, Mark
Wolleschak, Denise
Brüggemann, Monika
Haas, Simon
Ho, Anthony D.
Müller-Tidow, Carsten
Dreger, Peter
Schmitt, Michael
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03676504 at ClinicalTrials.govDocuments that mention this clinical trial
Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol (Pre-results)
https://doi.org/10.1136/bmjopen-2018-026644
Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial
https://doi.org/10.1186/s13045-023-01470-0
-
Funding
Funding for this research was provided by:
Olympia Morata Program of the Medical Faculty of the University of Heidelberg (OM 09/2019)
Frankfurter Förderung “Nachwuchswissenschaftler
EUTOS funding program
Carreras leukemia foundation (AH06-01)
Universitätsklinikum Heidelberg
- License Information
-
More Information
Article History
Received: 28 February 2023
Accepted: 20 June 2023
First Online: 22 July 2023
Declarations
:
: AS: Travel grants from Hexal and Jazz Pharmaceuticals. Research grant from Therakos/Mallinckrodt. Consultancy BMS, Janssen-Cilag. Co-founder and part-time employee of TolerogenixX LtD. of TolerogenixX Ltd. CMT: research support from Bayer AG. Advisory board member Pfizer, Janssen-Cilag GmbH. Grants and/or provision of investigational medicinal products from Pfizer, Daiichi Sankyo, BiolineRx. FL: Advisory roles for Novartis, Incyte, Sanofi Aventis and Bristol-Myers Squibb. GB: Research support from Novartis; Consultancy for Novartis, Pfizer, Gilead, Celgene; Honoraria from Jazz, Celgene, Gilead; Travel support from Neovii, Jazz, Gilead. JC: Travel grants: Pfizer, Ipsen, Medac; Adboard: Pfizer, Merck, Ipsen, MSD; Consultancy: Pfizer, Merck, Medac. JK: Consultancy Novartis, Global Blood Therapeutics, bluebird bio. MB: consulting fees from Amgen and PRMA, research funding from Amgen, honoraria/travel grants from Jazz, Celgene, Novartis, Pfizer and Amgen, advisory board member for Incyte and Amgen. MLS: consultancy for Kite/Gilead, Takeda. MS: research grants from Apogenix, Hexal and Novartis. Travel grants from Hexal and Kite. Financial support for educational activities and conferences from bluebird bio, Kite and Novartis. Advisory board member of MSD. (Co-)PI of clinical trials of MSD, GSK, Kite and BMS. Co-Founder and shareholder of TolerogenixX Ltd. PD: consultancy AbbVie, AstraZeneca, Gilead, Janssen, Novartis, Riemser, Roche; speakers bureau AbbVie, Gilead, Novartis, Riemser, Roche; research support from Neovii and Riemser. None of the mentioned sources supported the work described within this manuscript. PDe: honorarium from MSD. PWu: Research support from the German Red Cross Blood Service Baden-Württemberg – Hessen gGmbH. Advisory Board Member of Sanofi-Aventis. TS: Consultant AbbVie, Takeda, Astellas, Amgen, Bristol-Myers Squibb, Gilead, Ridgeline Discoveries. Honorarium: Pfizer, AbbVie, Jazz Pharmaceuticals. Financial support congress participation: AbbVie, Jazz Pharmaceuticals., ADH, AHK, AKei, AKul, AKun, AN, BM, BN, DH, DV, DW, FK, JF, LJS, LW, MG, MRi, NG, PP, PW, SH, SLa, SY: none.
